Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $55.00 at Barclays

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective increased by Barclays from $39.00 to $55.00 in a research note published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the medical device company’s stock.

TNDM has been the topic of several other research reports. Citigroup upped their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a research note on Wednesday, April 3rd. Stifel Nicolaus boosted their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a buy rating in a report on Tuesday, April 23rd. Robert W. Baird raised their price target on Tandem Diabetes Care from $28.00 to $36.00 and gave the stock a neutral rating in a report on Friday. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a market perform rating to an outperform rating in a research report on Thursday, April 25th. Finally, SVB Leerink raised Tandem Diabetes Care from a market perform rating to an outperform rating and boosted their price objective for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of Moderate Buy and a consensus target price of $43.80.

Tandem Diabetes Care Trading Down 2.7 %

Shares of TNDM stock opened at $43.50 on Monday. Tandem Diabetes Care has a one year low of $13.82 and a one year high of $47.00. The firm has a 50-day moving average of $32.58 and a 200-day moving average of $26.35. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. On average, equities research analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tandem Diabetes Care

Institutional investors and hedge funds have recently made changes to their positions in the business. RiverPark Advisors LLC purchased a new stake in Tandem Diabetes Care during the 4th quarter valued at $27,000. MCF Advisors LLC raised its holdings in Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after purchasing an additional 445 shares in the last quarter. Signaturefd LLC increased its position in shares of Tandem Diabetes Care by 871.8% during the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after buying an additional 1,517 shares during the period. Arcadia Investment Management Corp MI increased its stake in shares of Tandem Diabetes Care by 141.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock worth $66,000 after acquiring an additional 1,085 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 51.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after purchasing an additional 1,099 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.